Physician profile
David Harshman
NPI 1629057344
$638.58
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $80.46 · 2021: $131 · 2022: $11.97 · 2024: $55.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $55.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $55.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $143.53 | 2019-2024 | Repatha |
| Fujifilm Healthcare Americas Corporation | $131.45 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.68 | 2019-2020 | |
| Abbott Laboratories | $56.26 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $52.24 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $39.49 | 2019 | |
| Arbor Pharmaceuticals, INC. | $35.08 | 2019 | |
| Boston Scientific Corporation | $29.45 | 2019 | |
| Biotronik INC. | $21.87 | 2024 | |
| Irhythm Technologies, INC. | $16.86 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.33 | 2024 | |
| Novartis Pharmaceuticals Corporation | $13.87 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Harshman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.